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An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin
(LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF
comprised six once-weekly infusions of irinotecan 80mgm
 2, LV 500mgm
 2, 24-h 5-FU 2000mgm
 2, and ELF comprised three
once-daily doses of etoposide 120mgm
 2, LV 300mgm
 2, 5-FU 500mgm
 2. In all, 56 patients received ILF and 58 ELF. Median age
was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates
after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI)
0.29–1.13, P¼0.0766). Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR
0.56, 95% CI 0.33–0.97; P¼0.0467). For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to
treatment failure was 3.6 vs 2.2 months (P¼0.4542), and overall survival was 10.8 vs 8.3 months (P¼0.2818). Both regimens were
well tolerated, the main grade 3/4 toxicities being diarrhoea (18%, ILF) and neutropenia (57%, ELF). The data from this randomised
phase II study indicate that ILF provides a better response rate than ELF, and that ILF should be investigated further for the treatment
of metastatic gastric cancer.
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Gastric cancer is the fourth most common cancer in Europe and
the third leading cause of cancer mortality (Bray et al, 2002).
Although gastric cancer has declined over the past 50 years, the
incidence of tumours at the gastro-oesophageal junction has
increased (Blot et al, 1991). The use of chemotherapy for the
management of patients with advanced gastric cancer, who have
limited treatment options (Hohenberger and Gretschel, 2003), has
only become widely acceptable over the last 20 years (Glimelius
et al, 1997; Murad et al, 1993; Pyrhonen et al, 1995).
5-Fluorouracil (5-FU), usually in combination with leucovorin
(LV, also referred to as folinic acid), forms the basis of most
chemotherapy regimens used for the treatment of gastric cancer. A
randomised phase III trial compared combinations of 5-FU with
other active drugs in advanced gastric cancer: etoposide, LV and 5-
FU (ELF) vs infusional 5-FU plus cisplatin (FUP) vs 5-FU,
doxorubicin and methotrexate (FAMTX) (Vanhoefer et al, 2000).
The overall response rates (ORRs) ranged from 9% (ELF) to 20%
(FUP) and median survival times were between 6.7 months
(FAMTX) and 7.2 months (both ELF and FUP). The observed
differences were not statistically significant and there is still no
definitive regimen for the treatment of gastric cancer. The
combination of epirubicin, cisplatin and continuous infusion 5-
FU (ECF) has been proposed as a standard first-line therapy for
gastric cancer as a consequence of its significantly improved
response rate (46%) and survival (8.7 months) when compared
with FAMTX (Waters et al, 1999). More recently, ELF has been
shown to provide better disease control (complete response
(CR)þpartial response (PR)þstable disease (SD)) for patients
with proximal rather than distal tumours (85 vs 48%, P¼0.04)
(Schulze-Bergkamen et al, 2002). Tolerability, toxicity and ease of
administration have become major determinants for selecting an
appropriate therapy and ELF has emerged as a convenient, well-
tolerated regimen that can be administered on an outpatient basis
(Vanhoefer et al, 2000; Schulze-Bergkamen et al, 2002).
Irinotecan (CPT-11, Camptosar; Pfizer Oncology, New York,
USA) inhibits topoisomerase I thereby disrupting DNA replication
and cell division within tumour cells. Response rates between 20
and 23% have been reported for irinotecan monotherapy in
untreated gastric cancer (Futatsuki et al, 1994; Kohne et al, 2003).
In patients who had failed previous therapy, irinotecan
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s(180mgm
 2) combined with 5-FU (400mgm
 2, bolus) and LV
(125mgm
 2) followed by 5-FU infusion (1200mgm
 2 over 48h)
yielded a response rate of 29%, while a further 34% of patients
achieved SD (Assersohn et al, 2004). Irinotecan with bolus-LV/5-
FU in the first-line treatment of gastric cancer provided a response
rate of 22% (Blanke et al, 2001). However, this regimen (irinotecan
125mgm
 2,L V2 0m gm
 2 plus 5-FU 500mgm
 2, all given weekly
for 4 weeks followed by a 2-week rest) was associated with a high
incidence of severe diarrhoea (28%) and neutropenia (36%)
infection leading to substantial dose modifications (Blanke et al,
2001). By comparison, the combination of irinotecan with
continuous rather than bolus infusions of LV/5-FU exhibited a
lower incidence of grade 3 and 4 toxicities in colorectal cancer
patients (Douillard et al, 2000; Saltz et al, 2000; Bouzid et al, 2003).
Therefore, we have investigated a weekly dose of irinotecan
(80mgm
 2) in combination with LV (500mgm
 2) and continuous
5-FU (2000mgm
 2 over 24h) according to the AIO (Arbeitsge-
meinschaft Internistische Onkologie) regimen (i.e. ILF) in gastric
cancer patients. In a previous phase I study of ILF in the first- and
second-line treatment of gastric cancer, we observed a response
rate of 20% with a further 36% of patients reporting SD (Moehler
et al, 2003). Importantly, toxicity was sufficiently manageable to
allow outpatient-based treatment. Therefore, we initiated the
present randomised, controlled, phase II study to compare the
efficacy and safety of ILF with ELF in the first-line treatment of
metastatic gastric cancer.
PATIENTS AND METHODS
Patients
Eligible patients had untreated histologically proven gastric
adenocarcinoma, or adenocarcinoma of the oesophagogastric
junction with measurable metastatic disease and/or locally
recurrent nodal involvement, were aged between 18 and 75 years
with a Karnofsky performance score (KPS) X60 and a life
expectancy 412 weeks. Patients were required to have adequate
haematological (neutrophils X2.0 10
9l
 1, platelets
X150 10
9l
 1; haemoglobin X10gdl
 1), hepatic (total bilirubin
p1.25 upper normal limit (UNL); aspartate (AST) and alanine
(ALT) aminotransferases p3 UNL) and renal function (creati-
nine o1.25 UNL). Patients with previous cancer therapies were
excluded from the study.
All patients provided signed and dated consent before entering
the trial. The study was conducted in accordance with the
principles of the Declaration of Helsinki and Good Clinical
Practice guidelines and the protocol was initially approved by
the Ethics committee of Aerztekammer Rheinland-Pfalz and later
by all Ethics committees responsible for participating centres.
Study design and randomisation
This was an open-label, multicentre, phase II randomised trial with
two treatment arms. Patients were randomly assigned and
stratified according to centre, peritoneal involvement (yes/no)
and prior gastrectomy (yes/no). The randomisation process was
centralised and performed by the Coordination Centre for Clinical
Trials (KKS), Mainz, Germany.
Administration of study drugs and dose adjustment
Patients assigned to ILF (Arm A) received irinotecan 80mgm
 2
intravenously (i.v.) over 60–90min followed by LV 500mgm
 2 i.v.
over 60min and then 5-FU 2000mgm
 2 i.v. over 24h, on day 1.
Each cycle comprised six once-weekly treatments followed by a 13-
day rest period. Systemic prophylactic atropine (0.25mg) injec-
tions for irinotecan-related acute cholinergic symptoms were
allowed for the first cycle but not recommended. Prophylactic
treatment for delayed diarrhoea was not permitted. However,
patients were carefully informed of the potential risk of delayed
diarrhoea and neutropenia and the need for early intervention with
loperamide, metoclopramide, antibiotics, or hospitalisation and
parenteral rehydration in case of refractory diarrhoea (448h).
Antiemetic treatment was performed using metoclopramide or
HT-3 antagonists in a sequential manner. The prophylactic use of
colony-stimulating factors was not permitted.
Patients assigned to ELF (Arm B) received etoposide 120mgm
 2
i.v. over 60min, LV 300mgm
 2 i.v. over 5–10min and then 5-FU
500mgm
 2 bolus i.v. over 2–4min, on day 1. Each cycle
comprised three applications on consecutive days (1–3) followed
by an 18-day rest.
All study treatments were administered until disease progres-
sion, unacceptable toxicity or withdrawal of consent. In the event
of toxicity (defined by the National Cancer Institute of Canada
expanded common toxicity criteria; NCIC-CTC), treatment delays
or dose reductions could be applied as follows. If at any time
during a cycle there were moderate reductions in haematological
function (neutrophil count 0.5–1.5 10
9l
 1, platelet count 25–
75 10
9l
 1) or moderate diarrhoea or stomatitis (4grade 1), the
next administration could be delayed for up to 2 weeks. If at any
time haematological abnormalities were noted (neutrophils
o0.5 10
9l
 1, neutrophils o1 10
9l
 1 with infection or fever,
platelets o25 10
9l
 1) or if there were Xgrade 3 or 4 diarrhoea
or stomatitis, treatment had to be delayed until recovery to
moderate levels (as described above) after which the following
dose reductions were applied. For Arm A, 5-FU was reduced to
1600mgm
 2 and irinotecan to 65mgm
 2. For Arm B, in the case
of haematological toxicity, etoposide had to be reduced to
100mgm
 2 and 5-FU to 400mgm
 2, and in the case of diarrhoea
or stomatitis, 5-FU was reduced to 400mgm
 2. If a condition
persisted despite dose reduction, or if a patient experienced
myocardial infarction, treatment was terminated. In the case of
hand–foot syndrome, the dose of 5-FU was to be reduced by 20%.
Delayed diarrhoea was treated immediately with loperamide and
rehydration and, if associated with severe neutropenia, a broad-
spectrum antibiotic. Hospitalisation with i.v. rehydration was
required for grade 4 or persistent (448h) diarrhoea, concomitant
vomiting, fever, or KPS o60%.
Study evaluations
At baseline up to five measurable lesions per organ and 10 lesions
in total were to be identified as target lesions, measured using
computed tomography (CT), and recorded according to the
RECIST system (Response Evaluation Criteria In Solid Tumours;
Therasse et al, 2000). The sum of the longest diameters for all
target lesions was used as a reference for determining objective
tumour response. Tumour responses were evaluated at week 7,
week 14 and then every two cycles for patients receiving ILF or
every four cycles for patients receiving ELF. Responses were
determined according to RECIST as follows: complete response
was defined as the disappearance of all target and nontarget lesions
with no new lesions and confirmed by two observations at least 4
weeks apart; PR was defined as a reduction of 30% or more in the
sums of the longest diameters of all measurable lesions relative to
baseline with no new lesions; no change (NC) was defined as
neither sufficient shrinkage to qualify for PR nor sufficient
increase to qualify for progressive disease (PD) with no new
lesions; and PD was defined as X20% increase in the sum of the
longest diameters, the occurrence of nontarget lesions (e.g. pleural
effusion or ascites) or the appearance of brain metastases
independently of performance at sites outside the brain.
Safety and tolerability were assessed by regular clinical
examinations and assessments of adverse events (weekly, at the
end of treatment and at every 3 months of follow-up), disease
symptoms, KPS, haematological and biochemical parameters.
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The primary end point was objective clinical response (CRþPR)
based on an interim analysis following 14 weeks of treatment. The
one-sided exact Fisher’s test was used to compare the treatment
arms at the significance level a¼5%. The analyses were performed
on an intention-to-treat basis including all patients who were
treated in the study.
The secondary end points were ORR (for the entire treatment
period), time to progression, tumour growth control, time to
treatment failure (including progression, death or withdrawal) and
survival.
Time to event data were described by Kaplan–Meier estimates
and treatment groups were compared by log-rank test. Time to
event data were further evaluated by appropriate proportional
Cox’s models and results were summarised by hazard ratio point
and 95% confidence interval (CI) estimates, and P-values of Wald
w
2 test. Binary data were described by risk ratio (RR) point and
95% CI estimates and treatment groups were compared by exact
Fisher’s test. Binary data were further evaluated by appropriate
logistic regression models and were summarised by odds ratio
point and 95% CI estimates and P-values of Wald w
2 test. If not
specified otherwise, P-values are presented from two-sided tests
and two-sided 95% CI are presented. All analyses were performed
using SAS version 6.12.
RESULTS
Patient characteristics
In all, 120 patients from 17 centres in Germany were randomised
into the study between November 2000 and April 2003. Two
patients from Arm A and four from Arm B withdrew without
receiving study treatment; therefore, the intention-to-treat popula-
tion contained 114 patients (56 received ILF and 58 received ELF).
The baseline characteristics were well balanced between the two
treatment groups (Table 1). The median age of patients was 62
years and the median KPS was 90%. In around one-third (31%) of
patients, the primary tumour site was the oesophagogastric
junction, 62% of patients had liver metastases and in 77% two or
more organs were involved.
Response rates
The objective clinical response rates following 14 weeks of
treatment (primary end point) were 30% for ILF compared with
17% for ELF (RR 0.57, 95% CI 0.29–1.13, P¼0.0766). The ORRs
for the entire treatment period and including all assessments prior
to discontinuation were 43% (24 of the 56) for ILF and 24% (14 of
the 58) for ELF (Table 2). The increased response rate provided by
ILF compared with ELF was statistically significant (RR¼0.56;
95% CI¼0.33–0.97; P¼0.0467.) The tumour control rates
(CRþPRþNC) were 63% (35 of the 56) and 41% (24 of the 58),
respectively.
Logistic regression analysis indicated that a baseline KPS p80%
reduced the likelihood of a response by 59% compared with
patients whose KPS was greater than 80% (P¼0.038) (Table 3).
After adjustment for KPS, peritoneal involvement and surgery for
primary tumour, the regression model also demonstrated that ILF
was 138% more likely to provide a response when compared with
the ELF regimen (Table 3, P¼0.042).
Progression-free survival, treatment failure and overall
survival
At the last data cutoff, the median follow-up was 9.4 months in
Arm A and 5.8 months in Arm B. At this time, 96 of the 114
patients had died. Disease progression was the major cause of
death and accounted for 79% of patients in both treatment groups.
One patient from the ILF arm did not comply with the provided
recommendations for the treatment of prolonged grade 3
diarrhoea and consequently died (i.e. toxic death). One patient
in the ELF arm died from a cardiovascular event.
Compared with ELF, the ILF regimen extended median
progression-free survival, median time to treatment failure and
median overall survival (Table 4). However, when the treatment
groups were compared by log-rank test, there was no significant
difference between the two treatments for any of these parameters
(e.g. the Kaplan–Meier survival plot as shown in Figure 1).
Investigational analyses found that the risk of progression was
increased in patients with a primary tumour in the oesophago-
gastric junction and in those with metastatic involvement in two or
more organs (Table 3). As would be expected, the risk of death was
increased in patients with a low KPS, in those with two or more
involved organs and in those with peritoneal involvement who
received ELF (Table 3).
Table 1 Patient and disease characteristics at baseline (intention-to-treat
population)
Irinotecan+5-
FU/LV
Etoposide+5-
FU/LV
No. of exposed patients 56 58
Gender (n (%))
Male 40 (71) 49 (85)
Female 16 (29) 9 (16)
Age (years)
Median (range) 61 (41–73) 63 (34–76)
KPS
Median value 90 85
Distribution (n (%))
60+70 3 (5) 7 (12)
80 21 (38) 22 (38)
90 28 (50) 21 (36)
100 4 (7) 8 (14)
Primary tumour location (n (%))
Stomach 37 (66) 42 (72)
Oesophagogastric junction 19 (34) 16 (28)
Median time (months (range)) since
Histological confirmation 1.5 (0–181) 1.4 (0–65)
Diagnosis of metastasis 0.7 (0–12) 0.5 (0–13)
Prior surgery
Number with surgery (%) 29 (52) 31 (53)
Median months since surgery (range) 7.7 (0–181) 11.1 (0–65)
Location of metastases at entry (n (%))
Skin 0 1 (2)
Liver 34 (61) 37 (64)
Lung 12 (21) 5 (9)
Lymph nodes 40 (71) 47 (81)
Bone marrow 0 0
Bone 4 (7) 1 (2)
Peritoneum 10 (18) 11 (19)
Other 20 (36) 23 (40)
Number of involved organs (n (%))
1 13 (23) 13 (22)
2 25 (45) 25 (43)
3 15 (27) 18 (31)
4 3 (5) 2 (3)
KPS¼Karnofsky performance score.
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The median number of cycles administered in the study was two
for ILF (Arm A) and three for ELF (Arm B) (Table 5). Although the
median treatment duration period was over twice as long with ILF
than with ELF, there were more dose administration delays (70%)
and dose reductions (75%) with ILF than with ELF (52 and 45%,
respectively). The main reason for discontinuing study treatment
was disease progression; 54% of patients receiving ILF and 72%
receiving ELF. Although only one patient in each treatment group
withdrew because of treatment-related toxicity, five patients
receiving ILF and three patients receiving ELF either withdrew
consent or refused further treatment.
The incidence of grade 3/4 haematological toxicities was low in
both treatment groups with the exception of neutropenia, which
was reported by 57% of patients receiving ELF (Table 6). There
were more grade 3/4 gastrointestinal toxic events with ILF, notably
diarrhoea, which was reported by 18% of patients compared with
no reports with ELF. Grade 3/4 alopecia was reported by a
significant proportion of patients receiving ELF (28%), but was
only seen in 5% of those receiving ILF.
DISCUSSION
Although chemotherapy regimens offer at best a slight, albeit
statistically significant, improvement in survival for patients with
gastric cancer, they are associated with a degree of toxicity that
limits their value as a palliative treatment (Vanhoefer et al, 2000;
Schoffski, 2002; Diaz-Rubio, 2004).
The primary end point of clinical response at 14 weeks was
selected so that a statistical comparison at a fixed time point could
be made. However, as it is the convention in such studies, patients
were treated until progression, and could respond to treatment at a
later point. Therefore, the overall response and survival rates
obtained from the entire dosing period provide a more clinically
significant assessment of the efficacy of these regimens for
discussion in relation to other trials in gastric cancer. The
irinotecan-based combination provided again a greater ORR than
that seen with the commonly used ELF regimen (43 vs 24%,
respectively, P¼0.0467).
Overall response rates for ELF reported in previous studies
range from 9 to 23% (Vanhoefer et al, 2000; Schulze-Bergkamen
et al, 2002) and this compares well with the 24% response rate
reported in this study. Accordingly, an ORR of nearly 50% for ILF,
as seen in this study, is a substantial improvement and is in the
Table 3 Exploratory analysis of effects of prognostic factors on clinical
outcome
End point Factor RR (95% CI)
Response Peritoneal involvement: 0.43
Yes vs no (0.13–1.47)
Surgery of primary tumour: 1.78
Yes vs no (0.76–4.15)
Baseline Karnofsky status: 0.41*
p80 vs 480 (0.17–0.95)
Treatment effect: 0.42*
ELF vs ILF (0.18–0.97)
Progression Peritoneal involvement: 1.15
Yes vs no (0.67–1.96)
Surgery of primary tumour: 0.86
Yes vs no (0.58–1.29)
ELF vs ILF 1.7
(in patients with Karnofsky status
p80)
(0.96–3.0)
ELF vs ILF 0.8
(in patients with Karnofsky status
480)
(0.47–1.39)
Number of organs: 1.99**
41 vs 1 (1.21–3.28)
Site of primary tumour: 1.91**
oesophagogastric vs stomach (1.2–3.04)
Death Peritoneal involvement: 0.85
Yes vs no (0.42–1.75)
Surgery of primary tumour: 0.69
Yes vs no (0.46–1.06)
ELF vs ILF 2.41
(in patients with peritoneal
involvement)
(0.99–5.82)
ELF vs ILF 1.01
(in patients without peritoneal
involvement)
(0.64–1.59)
Number of organs: 2.56**
41 vs 1 (1.48–4.42)
Baseline Karnofsky status: 1.84**
p80 vs 480 (1.21–2.8)
RR¼risk ratio; CI¼confidence interval. A risk value 41 shows an increased
likelihood of the clinical outcome in favour of the first of the two compared terms.
ELF, etoposide+LV (leucovorin)+5-FU(5-fluorouracil); ILF, irinotecan+LV+5-FU; EJ,
oesophagogastric junction. *Po0.05. **o0.01 by Wald w
2 test.
Table 4 Survival
Irinotecan+5-
FU/LV (N¼56)
Etoposide+5-
FU/LV (N¼58)
Survival
parameter Median time in months (95% CI)
Statistical
comparison
a
Hazard ratio
(95% CI)
Progression-free
survival
4.5 (3.4–5.8) 2.3 (2.0–4.7) 1.10 (0.75–1.62)
P¼0.6116
Time to treatment
failure
3.6 (2.4–5.1) 2.2 (1.5–2.9) 1.15 (0.79–1.67)
P¼0.4542
Overall survival 10.8 (9.0–13.2) 8.3 (6.6–11.4) 1.25 (0.83–1.86)
P¼0.2818
5-FU¼5-fluorouracil; LV¼leucovorin; CI¼confidence interval.
aHazard ratio 41
favors irinotecan+5-FU/LV; P-value from log-rank test.
Table 2 Response to therapy in the entire treatment period
Number (%) of patients
Response category
Irinotecan+5-FU/LV
(N¼56)
Etoposide+5-FU/LV
(N¼58)
CR 2 (4) 0
PR 22 (39) 14 (24)
NC 11 (20) 10 (17)
PD 13 (23) 27 (47)
Missing 8 (14) 7 (12)
Overall response (CR+PR) 24 (43) 14 (24)
RR (95% CI), P-value
0.56 (0.33–0.97),
P¼0.0467
Disease control
(CR+PR+NC)
35 (63) 24 (41)
5-FU¼5-fluorouracil; LV¼leucovorin; CR¼Complete response; PR¼partial re-
sponse; NC¼no change; PD¼progressive disease; RR¼risk ratio; CI¼confidence
interval.
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srange of previous reports of the use of this drug combination in
this setting (Blanke et al, 2001; Moehler et al, 2003).
The overall survival data in the present study also compare well
with those from previous studies. The median overall survival with
ELF has been reported at 7.2 and 8.0 months (Vanhoefer et al,
2000; Schulze-Bergkamen et al, 2002), which is similar to both the
8.3 months reported here and the data reported for irinotecan-
based regimens in the second-line setting between 7.0 and 7.6
months (Moehler et al, 2003; Assersohn et al, 2004). By
comparison, there was a nonsignificant trend for increased median
survival with ILF in this study (10.8 months) and this compares
well with data reported for more recent exploratory combinations
such as capecitabine and docetaxel (10.5 months), and epirubicin,
docetaxel and cisplatin (11.0 months) (Lee et al, 2004; Park et al,
2004). The same can be said of the progression-free survival period
in the ILF group of 4.5 months, which compared well with the 4.1
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Figure 1 Overall survival. Arm A¼irinotecanþ5-fluorouracil/leucovorin (ILF), N¼56. Arm B¼etoposideþ5-fluorouracil/leucovorin (ELF), N¼58.
Table 5 Dosing information
Irinotecan+5-
FU/LV (N¼56)
Etoposide+5-
FU/LV (N¼58)
Median number of
cycles (range)
2 (0–14) 3 (1–19)
Number of cycles
administered as
planned
33 (59%) 48 (82%)
Median months of
treatment duration
(range)
3.6 (0–22) 1.5 (0–15)
Number (%) of
administration
delays
39 (70) 30 (52)
Number (%) of
dose reductions
42 (75) 26 (45)
5-FU¼5-fluorouracil; LV¼leucovorin.
Table 6 Grade 3 or 4 toxicity according to NCIC-CTC
Irinotecan+5-
FU/LV (N¼56)
Etoposide+5-
FU/LV (N¼58)
Adverse event category
Percentage of patients in each
category
Haematological toxicity
Anaemia 7 9
Neutropenia 9 57
Thrombocytopenia 4 5
Infection with neutropenia 4 3
Fever+neutropenia, no infection 2 3
Gastrointestinal toxicity
Nausea 16 7
Diarrhoea 18 0
Vomiting 7 5
Other toxicity
Infection without neutropenia 2 7
Anorexia 2 7
Alopecia 5 28
Constipation 2 0
NCIC-CTC¼National Cancer Institute of Canada expanded common toxicity
criteria; 5-FU¼5-fluorouracil; LV¼leucovorin.
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(Lee et al, 2004; Park et al, 2004). In other randomised phase II
studies, continuous 5-FU/LV infusion plus irinotecan has also
provided promising efficacy (ORRs of 40–42%, median progres-
sion-free survival periods of 6.5–6.9 months and median overall
survival periods of 10.7–11.3 months; Bouche et al, 2004; Pozzo
et al, 2004). Consequently, large phase III studies are being
considered to investigate irinotecan in combination with contin-
uous 5-FU/LV infusion regimens.
When patient histories, disease status and other factors were
examined for their effects on clinical outcome, those patients who
were in better general health (good performance status, low
tumour burden) were more likely to achieve a response and less
likely to have a progression event or die, regardless of the
treatment arm to which they were randomised. Patients with
peritoneal involvement at presentation have a generally poorer
prognosis and as a group face a desperate need for improved
treatment options (Rau et al, 1996). The data from this study
demonstrated that these patients are less likely to suffer a fatal
event if treated with ILF rather than ELF. This is potentially an
important observation for the management of these difficult to
treat patients (Blot et al, 1991; Bray et al, 2002).
The extension of meaningful survival remains a major objective
for oncologists who must therefore consider the impact of
treatment-related toxicity. Overall, the occurrence of the toxicities
in this study was consistent with the safety profiles of irinotecan,
etoposide and 5-FU/LV. The ILF combination was well tolerated
with a low and acceptable incidence of haematological toxicity.
Gastrointestinal toxicity is a recognised side effect of ILF therapy
(Douillard et al, 2000; Saltz et al, 2000), which can require
hospitalisation and urgent medical intervention (Rothenberg et al,
2001). The incidence of grade 3 or 4 diarrhoea in the current study
was comparable to the previous data in gastric cancer (Blanke et al,
2001; Moehler et al, 2003; Pozzo et al, 2004). With close
monitoring of the patient, suitable medication and rehydration,
most cases of diarrhoea can be managed effectively and do not
present a significant obstacle to the clinical use of ILF.
The toxicity observed in our study was lower than that reported
by Douillard et al in the pivotal European first-line trial where
patients with colorectal cancer received weekly irinotecan
(80mgm
 2) plus an AIO-based regimen of 24-h high-dose 5-FU
(2300mgm
 2) preceded by 2-h LV 500mgm
 2, and grade 3/4
diarrhoea was reported by 44% of patients (Douillard et al, 2000).
The lower toxicity in our study might be due to the lower daily
doses of 5-FU (2000mgm
 2 administered over 24h). Work is
ongoing to identify those patients who carry a specific genetic
polymorphism in one of the main enzymes (UGT1A1) involved in
the detoxification of irinotecan and are therefore more susceptible
to the side effects of irinotecan (Mathijssen et al, 2001). Such work
will improve the targeting of this useful therapy and may allow
appropriate prescriptive dosing schedules on an individual basis.
The present study concurs with similar phase II studies in that
the combination of irinotecan with continuous LV/5-FU (ILF)
represents a potentially valuable new treatment option for
metastatic gastric cancer and requires further evaluation (Bouche
et al, 2004; Pozzo et al, 2004).
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